Zahl Eriksson Ane Gerda, Ducie Jen, Ali Narisha, McGree Michaela E, Weaver Amy L, Bogani Giorgio, Cliby William A, Dowdy Sean C, Bakkum-Gamez Jamie N, Abu-Rustum Nadeem R, Mariani Andrea, Leitao Mario M
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Gynecol Oncol. 2016 Mar;140(3):394-9. doi: 10.1016/j.ygyno.2015.12.028. Epub 2015 Dec 31.
To assess clinicopathologic outcomes between two nodal assessment approaches in patients with endometrioid endometrial carcinoma and limited myoinvasion.
Patients with endometrial cancer at two institutions were reviewed. At one institution, a complete pelvic and para-aortic lymphadenectomy to the renal veins was performed in select cases deemed at risk for nodal metastasis due to grade 3 cancer and/or primary tumor diameter>2cm (LND cohort). This is a historic approach at this institution. At the other institution, a sentinel lymph node mapping algorithm was used per institutional protocol (SLN cohort). Low risk was defined as endometrioid adenocarcinoma with myometrial invasion <50%. Macrometastasis, micrometastasis, and isolated tumor cells were all considered node-positive.
Of 1135 cases identified, 642 (57%) were managed with an SLN approach and 493 (43%) with an LND approach. Pelvic nodes (PLNs) were removed in 93% and 58% of patients, respectively (P<0.001); para-aortic nodes (PANs) were removed in 14.5% and 50% of patients, respectively (P<0.001). Median number of PLNs removed was 6 and 34, respectively; median number of PANs removed was 5 and 16, respectively (both P<0.001). Metastasis to PLNs was detected in 5.1% and 2.6% of patients, respectively (P=0.03), and to PANs in 0.8% and 1.0%, respectively (P=0.75). The 3-year disease-free survival rates were 94.9% (95% CI, 92.4-97.5) and 96.8% (95% CI, 95.2-98.5), respectively.
Our findings support the use of either strategy for endometrial cancer staging, with no apparent detriment in adhering to the SLN algorithm. The clinical significance of disease detected on ultrastaging and the role of adjuvant therapy is yet to be determined.
评估两种淋巴结评估方法在子宫内膜样子宫内膜癌伴有限肌层浸润患者中的临床病理结局。
对两家机构的子宫内膜癌患者进行回顾性研究。在一家机构,对于因3级癌症和/或原发肿瘤直径>2cm而被认为有淋巴结转移风险的特定病例,进行至肾静脉水平的完整盆腔及腹主动脉旁淋巴结清扫术(淋巴结清扫队列)。这是该机构过去采用的方法。在另一家机构,按照机构方案采用前哨淋巴结映射算法(前哨淋巴结队列)。低风险定义为肌层浸润<50%的子宫内膜样腺癌。大转移灶、微转移灶和孤立肿瘤细胞均视为淋巴结阳性。
在1135例确诊病例中,642例(57%)采用前哨淋巴结方法处理,493例(43%)采用淋巴结清扫方法处理。分别有93%和58%的患者切除了盆腔淋巴结(PLNs)(P<0.001);分别有14.5%和50%的患者切除了腹主动脉旁淋巴结(PANs)(P<0.001)。切除的PLNs中位数分别为6个和34个;切除的PANs中位数分别为5个和16个(均P<0.001)。分别有5.1%和2.6%的患者检测到PLNs转移(P=0.03),分别有0.8%和1.0%的患者检测到PANs转移(P=0.75)。3年无病生存率分别为94.9%(95%CI,92.4 - 97.5)和96.8%(95%CI,95.2 - 98.5)。
我们的研究结果支持在子宫内膜癌分期中使用这两种策略中的任何一种,采用前哨淋巴结算法并无明显不利影响。超分期检测到的疾病的临床意义以及辅助治疗的作用尚待确定。